Hypertension Diagnostics Inc
Hypertension Diagnostics, Inc. designs, develops, manufactures, and markets proprietary noninvasive medical devices that detect subtle changes in the elasticity of arteries in the United States and internationally. It offers CVProfilor, which allows a physician to non-invasively assess the elasticity of small and large arteries, of which small artery elasticity is the earliest and sensitive marke… Read more
Hypertension Diagnostics Inc (HDII) - Net Assets
Latest net assets as of June 2021: $-262.39K USD
Based on the latest financial reports, Hypertension Diagnostics Inc (HDII) has net assets worth $-262.39K USD as of June 2021.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.08 Million) and total liabilities ($1.34 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-262.39K |
| % of Total Assets | -24.26% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -238.43% |
| Growth Volatility | 344.56 |
Hypertension Diagnostics Inc - Net Assets Trend (1997–2021)
This chart illustrates how Hypertension Diagnostics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Hypertension Diagnostics Inc (1997–2021)
The table below shows the annual net assets of Hypertension Diagnostics Inc from 1997 to 2021.
| Year | Net Assets | Change |
|---|---|---|
| 2021-06-30 | $-913.71K | 0.00% |
| 2020-12-31 | $-913.71K | +11.92% |
| 2020-06-30 | $-1.04 Million | 0.00% |
| 2019-12-31 | $-1.04 Million | +77.58% |
| 2017-12-31 | $-4.63 Million | -8.66% |
| 2016-12-31 | $-4.26 Million | -1374.97% |
| 2012-12-31 | $-288.67K | -168.84% |
| 2011-06-30 | $419.36K | 0.00% |
| 2010-12-31 | $419.36K | -36.46% |
| 2009-06-30 | $660.04K | 0.00% |
| 2008-12-31 | $660.04K | -53.72% |
| 2007-12-31 | $1.43 Million | -22.51% |
| 2006-12-31 | $1.84 Million | +14.77% |
| 2005-12-31 | $1.60 Million | -0.24% |
| 2004-12-31 | $1.61 Million | +1213.71% |
| 2003-12-31 | $122.36K | -95.11% |
| 2002-12-31 | $2.50 Million | -53.11% |
| 2001-12-31 | $5.33 Million | -0.59% |
| 2000-12-31 | $5.37 Million | -36.88% |
| 1999-12-31 | $8.50 Million | +507.14% |
| 1997-12-31 | $1.40 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Hypertension Diagnostics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2769140500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2022)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.13 Million | % |
| Other Comprehensive Income | $-2.13 Million | % |
| Other Components | $30.87 Million | % |
| Total Equity | $-121.89K | 100.00% |
Hypertension Diagnostics Inc Competitors by Market Cap
The table below lists competitors of Hypertension Diagnostics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
XIWANG SPECIAL STEE (2XI.SG)
STU:2XI
|
$0.98 |
|
WayPoint Biomedical Holdings Inc
PINK:WYPH
|
$0.98 |
|
Sixty Six Oilfield Services Inc
PINK:SSOF
|
$0.98 |
|
Upper Street Marketing Inc
PINK:UPPR
|
$0.98 |
|
Alabama Aircraft Industries Inc
PINK:AAIIQ
|
$0.97 |
|
Orpheum Property Inc
PINK:PLFF
|
$0.97 |
|
Vydrotech Inc
PINK:VYDR
|
$0.97 |
|
QENEX Communications Inc
PINK:QNXC
|
$0.97 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hypertension Diagnostics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from -121,895 to -121,895, a change of 0.
- Net loss of 93,247 reduced equity.
- Other factors increased equity by 93,247.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-93.25K | -76.5% |
| Other Changes | $93.25K | +76.5% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Hypertension Diagnostics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1997-12-31 | $0.61 | $0.00 | x |
| 1999-12-31 | $1.71 | $0.00 | x |
| 2000-12-31 | $1.05 | $0.00 | x |
| 2001-12-31 | $0.99 | $0.00 | x |
| 2002-12-31 | $0.42 | $0.00 | x |
| 2003-12-31 | $0.01 | $0.00 | x |
| 2004-12-31 | $0.07 | $0.00 | x |
| 2005-12-31 | $0.06 | $0.00 | x |
| 2006-12-31 | $0.05 | $0.00 | x |
| 2007-12-31 | $0.04 | $0.00 | x |
| 2008-12-31 | $0.02 | $0.00 | x |
| 2009-06-30 | $0.02 | $0.00 | x |
| 2010-12-31 | $0.01 | $0.00 | x |
| 2011-06-30 | $0.01 | $0.00 | x |
| 2012-12-31 | $-0.01 | $0.00 | x |
| 2016-12-31 | $-0.08 | $0.00 | x |
| 2017-12-31 | $-0.05 | $0.00 | x |
| 2019-12-31 | $-0.01 | $0.00 | x |
| 2020-06-30 | $-0.01 | $0.00 | x |
| 2020-12-31 | $-0.01 | $0.00 | x |
| 2021-06-30 | $-0.01 | $0.00 | x |
| 2021-12-31 | $0.00 | $0.00 | x |
| 2022-06-30 | $0.00 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hypertension Diagnostics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-163.56%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1997 | -78.57% | -1100.00% | 0.06x | 1.14x | $-1.24 Million |
| 1999 | -25.88% | -550.00% | 0.05x | 1.02x | $-3.05 Million |
| 2000 | -61.96% | -784.91% | 0.07x | 1.08x | $-3.86 Million |
| 2001 | -42.28% | -110.16% | 0.35x | 1.09x | $-2.79 Million |
| 2002 | -254.69% | -1159.87% | 0.13x | 1.72x | $-6.62 Million |
| 2003 | -3107.35% | -490.37% | 0.67x | 9.44x | $-3.81 Million |
| 2004 | -114.47% | -171.16% | 0.48x | 1.40x | $-2.00 Million |
| 2005 | -90.74% | -123.10% | 0.54x | 1.37x | $-1.62 Million |
| 2006 | -69.17% | -71.12% | 0.76x | 1.27x | $-1.46 Million |
| 2007 | -35.34% | -26.83% | 0.93x | 1.42x | $-646.63K |
| 2008 | -37.57% | -49.29% | 0.49x | 1.56x | $-314.00K |
| 2009 | -37.64% | -49.37% | 0.49x | 1.56x | $-314.44K |
| 2010 | 96.89% | 29.25% | 1.08x | 3.07x | $364.38K |
| 2011 | 96.89% | 29.25% | 1.08x | 3.07x | $364.38K |
| 2012 | 0.00% | -36.10% | 2.42x | 0.00x | $-1.11 Million |
| 2016 | 0.00% | -17.44% | 2.54x | 0.00x | $-196.22K |
| 2017 | 0.00% | -10.02% | 2.47x | 0.00x | $94.03K |
| 2019 | 0.00% | 86.87% | 3.51x | 0.00x | $3.40 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $3.40 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $80.37K |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $80.37K |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-81.06K |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-81.06K |
Industry Comparison
This section compares Hypertension Diagnostics Inc's net assets metrics with peer companies in the Shell Companies industry.
Industry Context
- Industry: Shell Companies
- Average net assets among peers: $36,677,338
- Average return on equity (ROE) among peers: -64.57%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hypertension Diagnostics Inc (HDII) | $-262.39K | -78.57% | N/A | $0.98 |
| Artius II Acquisition Inc. Class A Ordinary Shares (AACB) | $-60.27K | 0.00% | 0.00x | $198.37 Million |
| Artius II Acquisition Inc. Units (AACBU) | $-60.27K | 0.00% | 0.00x | $205.28 Million |
| Ares Acquisition Corporation II (AACT-UN) | $931.34 Million | 0.00% | 0.08x | $399.77 Million |
| AA Mission Acquisition Corp. (AAM-UN) | $-559.90 Million | 0.00% | 0.00x | $349.76 Million |
| Global Acquisitions Corporation (AASP) | $3.80 Million | -5.26% | 0.34x | $15.42 Million |
| ABV Consulting Inc (ABVN) | $8.75K | -623.31% | 2.50x | $461.96K |
| Atlantic Coastal Acquisition Corp II (ACAB) | $-8.52 Million | 0.00% | 0.00x | $2.44 Million |
| Annabidiol Corp (ACBD) | $-501.57K | 0.00% | 0.00x | $13.62K |
| ACRO Biomedical Co Ltd (ACBM) | $685.87K | -17.12% | 0.46x | $30.04K |
| Huaizhong Health Group Inc (ADAD) | $-19.47K | 0.00% | 0.00x | $3.15K |